These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System. Jhaveri KD; Sakhiya V; Wanchoo R; Ross D; Fishbane S Kidney Int; 2016 Sep; 90(3):706-7. PubMed ID: 27521117 [No Abstract] [Full Text] [Related]
3. Onconephrology: What Should the Internist Know About Targeted Therapy in Solid Tumors? El Rassy E; El Karak F; Rizkallah J; Chelala D Iran J Kidney Dis; 2016 Jul; 10(4):169-75. PubMed ID: 27514761 [TBL] [Abstract][Full Text] [Related]
4. How to keep kidneys safe while shrinking tumors: the conundrum of cisplatin action. Goligorsky MS Am J Physiol Renal Physiol; 2007 Jul; 293(1):F50-1. PubMed ID: 17507601 [No Abstract] [Full Text] [Related]
8. [New drugs in oncology: benefits, risks and challenges]. Cella D; Vervölgyi V; Wörmann B Onkologie; 2013; 36 Suppl 5():12-9. PubMed ID: 23921801 [No Abstract] [Full Text] [Related]
9. Is tumor response important for renal carcinoma? Inman BA; George DJ Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245 [No Abstract] [Full Text] [Related]
11. [Managing cutaneous toxicities of targeted therapies]. Kiyohara Y Gan To Kagaku Ryoho; 2012 Nov; 39(11):1597-602. PubMed ID: 23152009 [TBL] [Abstract][Full Text] [Related]
12. Importance of monitoring renal function in patients with cancer. Aapro M; Launay-Vacher V Cancer Treat Rev; 2012 May; 38(3):235-40. PubMed ID: 21605937 [TBL] [Abstract][Full Text] [Related]